2179 — Jiangsu Recbio Technology Co Income Statement
0.000.00%
Last trade - 00:00- HK$3.64bn
- HK$4.11bn
Annual income statement for Jiangsu Recbio Technology Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 142 | 601 | 732 | 559 | 543 |
| Operating Profit | -142 | -601 | -732 | -559 | -543 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -179 | -658 | -736 | -572 | -562 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -179 | -658 | -736 | -572 | -562 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -179 | -658 | -723 | -572 | -562 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -179 | -658 | -723 | -572 | -562 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.374 | -1.33 | -1.5 | -1.18 | -1.17 |